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The type I TGFβ receptor TGFβRI (encoded by Tgfbr1) was ab-
lated in cartilage. The resulting Tgfbr1Col2 mice exhibited lethal
chondrodysplasia. Similar defects were not seen in mice lacking the
type II TGFβ receptor or SMADs 2 and 3, the intracellular mediators of
canonical TGFβ signaling. However, we detected elevated BMP activ-
ity in Tgfbr1Col2 mice. As previous studies showed that TGFβRI can
physically interact with ACVRL1, a type I BMP receptor, we gener-
ated cartilage-specific Acvrl1 (Acvrl1Col2) and Acvrl1/Tgfbr1 (Acvrl1/
Tgfbr1Col2) knockouts. Loss of ACVRL1 alone had no effect, but
Acvrl1/Tgfbr1Col2 mice exhibited a striking reversal of the chondro-
dysplasia seen in Tgfbr1Col2 mice. Loss of TGFβRI led to a redistri-
bution of the type II receptor ACTRIIB into ACVRL1/ACTRIIB
complexes, which have high affinity for BMP9. Although BMP9 is
not produced in cartilage, we detected BMP9 in the growth plate,
most likely derived from the circulation. These findings demon-
strate that the major function of TGFβRI in cartilage is not to trans-
duce TGFβ signaling, but rather to antagonize BMP signaling
mediated by ACVRL1.
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Growth plate cartilage supports bone elongation and providesan essential platform for the generation of articular joints
(1). Cartilage is generated by chondrocytes, which can be clas-
sified into different subtypes depending on their location and
differentiation status (1). These subtypes form distinct zones in
the growth plate. The pool of resting chondrocytes at the distal
ends of developing long bones supplies cells for building growth
plate cartilage. Resting chondrocytes differentiate into columnar
chondrocytes, which have a high proliferative rate and stack to-
gether into columns. Columnar cells further differentiate into
prehypertrophic chondrocytes, which cease proliferation and en-
large. These cells further differentiate into hypertrophic chon-
drocytes, which have a larger cell size and eventually undergo
apoptosis or transdifferentiate into osteoblasts (2). Eventually, the
growth plate is replaced by calcified bone.
TGFβ and bone morphogenetic protein (BMP) signaling
components play important roles in cartilage and joint formation
and maintenance (3–7). TGFβs 1 to 3 bind to complexes con-
taining the type I receptor TGFβRI and the type II receptor
TGFβRII. Ligand binding triggers phosphorylation of TGFβRI,
enabling activation of the intracellular mediators SMADs 2 and
3 in the canonical TGFβ pathway. TGFβs also signal through
activation of kinases such as MAP kinase, TAK1, JNK, and
RhoA. BMPs are a diverse group of ligands that share homology
to TGFβs 1 to 3, but bind to distinct receptor complexes consisting of
type I (ACVRL1 [ALK1], ACVR1 [ALK2], BMPR1A [ALK6], and
BMPR1B [ALK3]) and type II receptors (ACTRIIA, ACTRIIB, and
BMPRII) (8). These complexes activate the intracellular SMADs 1/5/8
in the canonical pathway, as well as noncanonical pathways over-
lapping with those activated by TGFβ. In addition to shared non-
canonical pathways, there is cross talk between TGFβ and BMP
pathways at multiple levels (3, 9, 10).
Although the potent in vitro chondrogenic activity of TGFβs is
well documented (11), the function of TGFβ pathways in carti-
lage in vivo is unclear. TGFβRII is the type II receptor for
TGFβs 1 to 3. Tgfbr2Col2 mice exhibit axial skeletal defects but
have no alterations in appendicular elements (12). Similarly, loss
of Smad3, Smad2, or both in chondrocytes leads to no or only
subtle growth plate phenotypes at birth (13, 14). These studies
may not reflect all TGFβ pathway activity in committed chon-
drocytes. Targeting SMADs 2 and 3 leaves noncanonical pathways
intact. Studies based on loss of TGFβRII may also underestimate
TGFβ pathway activity; in cranial neural crest cells, TGFβs acti-
vate TGFβ signaling in the absence of TGFβRII (15). Further-
more, ligands other than TGFβs 1 to 3 (e.g., GDF8, GDF10, and
GDF11) can activate signaling through TGFβRI in complexes
containing ACTRIIA or ACTRIIB (16–18).
These findings raise the possibility that TGFβRI acts in-
dependently of TGFβRII in cartilage. A study of Tgfbr1Dermo1
mice showed that TGFβRI plays a critical role in formation of
the perichondrium adjacent to the growth plate (19). Whether
TGFβRI has a role in growth plate chondrocytes has not been
investigated. TGFβRI is also of interest because it enables TGFβs
to activate BMP signaling through a mechanism involving asso-
ciation of the BMP receptor ACVRL1 with TGFβRI/TGFβRII
complexes (20, 21). TGFβ signaling through ACVRL1/TGFβRI/
TGFβRII complexes augments BMP signaling in vascular cells
(21). Whether such complexes exist in other tissues, and their
impact on BMP signaling, is unclear.
Using mice lacking TGFβRI in cartilage (Tgfbr1fx/fx;Col2-
Cre [Tgfbr1Col2]), we find that TGFβRI is required to maintain
the pool of resting chondrocytes in the growth plate. Unexpectedly,
the primary function of TGFβRI is not to activate TGFβ path-
ways. Rather, Tgfbr1Col2 mice exhibit elevated BMP activity
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mediated by ACVRL1. Mechanistically, loss of TGFβRI triggers
the formation of ACVRL1/ACTRIIB complexes in the growth
plate. These have high affinity for the circulating BMP ligand
BMP9, which we detected in growth plate cartilage. Thus, these
studies indicate that the major function of the type I TGFβ re-
ceptor in growth plate cartilage is to prevent the promiscuous
activation of ACVRL1-mediated BMP signaling by the circu-
lating ligand BMP9.
Results
TGFβRI Is Expressed in Growth Plate Cartilage during Embryonic
Development. We examined when and where TGFβRI is
expressed to understand its potential roles in the growth plate.
Tgfbr1Col2 mice were used as negative controls for antibody
specificity and confirmed that TGFβRI is efficiently deleted (SI
Appendix, Fig. S1G and J). At embryonic day 13.5 (E13.5), TGFβRI
is expressed in intervertebral discs, and at lower levels in chon-
drocytes within vertebral bodies (SI Appendix, Fig. S1A). TGFβRI
is expressed primarily in the perichondrium of appendicular ele-
ments at E13.5 but is present at low levels in chondrocytes (SI
Appendix, Fig. S1 B–E). TGFβRI expression in appendicular
growth plates is increased by E16.5 (SI Appendix, Fig. S1 F and G)
and persists at least through E18.5 (SI Appendix, Fig. S1 I and J).
Expression is strong at E16.5 and E18.5 in the columnar zone
(CZ) but is absent from the hypertrophic zone (HZ) (SI Appendix,
Fig. S1 F and I). At E16.5, resting chondrocytes in the developing
posterior tibial condyle exhibit higher TGFβRI levels than do
those in the anterior condyle (SI Appendix, Fig. S1F [yellow and
white boxes] and SI Appendix, Fig. S1H). At E18.5, TGFβRI pro-
tein levels are high in resting zone (RZ) chondrocytes throughout
the growth plate, and in the anterior and posterior condyles (SI
Appendix, Fig. S1 I and K).
Severe Chondrodysplasia in Tgfbr1 Mutant Neonates. Analysis of
Tgfbr1Dermo1 mice demonstrated a major role for TGFβRI in
formation of the perichondrium (19). However, becauseDermo1-cre
is expressed in many mesodermal-derived tissues, whether
TGFβRI had a direct function in chondrocytes could not be de-
termined. We therefore generated Tgfbr1f/f;Col2-Cre (Tgfbr1Col2)
mice to delete TGFβRI specifically in chondrocytes. The resulting
Tgfbr1Col2 mice exhibited perinatal lethality. The precise cause of
death is unknown, but mutants exhibit major skeletal defects. At
E13.5 and E14.5, there are no patterning defects in Tgfbr1Col2
mice, but mutants have smaller vertebrae and occipital bones; no
obvious defects in appendicular elements are seen at these stages
(Fig. 1 A and B). At E16.5, defects in Tgfbr1Col2 axial elements
persist; mutants develop abnormal spinal curvature and kinks in
the ribs at the chondro-osseous junction along with shortened
sternebrae (Fig. 1C). There are no defects in appendicular pat-
terning at E16.5, but long bones are shorter by this stage (Fig. 1 E,
F, and K).
At E18.5, the severity of skeletal defects in the Tgfbr1Col2 mice
continues to progress. Tgfbr1Col2 mice have shorter statures
(E16.5: Mut/Ctrl, 87.2% ± 2%; E18.5: Mut/Ctrl, 73.9% ± 3%)
and shorter tibiae than controls (Fig. 1 C, D, F, H, K, and L).
E18.5 Tgfbr1Col2 mice have bent scapulae, kinks at the distal ends
of humeri, and dislocation of elbow joints (Fig. 1 G and I); these
defects are not present at E16.5 (Fig. 1E). The condyles and
entheses of tibiae are also smaller in mutants at E18.5 (Fig. 1 H
and J). The proximal tibial cartilage is no different in length (Fig.
1M), but is wider in Tgfbr1Col2 mice than in control littermates at
E18.5 (Fig. 1O), and both the length and width of distal femoral
cartilage are larger in Tgfbr1Col2 mice (Fig. 1 N and P). As these
defects are not seen in Tgfbr2Col2 mutants (12) or Smad2Col2/
Smad3−/− mice (13), TGFβRI must transduce its effects in
chondrocytes in combination with a different type II receptor,
and through a pathway other than the canonical TGFβ pathway.
Chondrocyte Proliferation and Differentiation Defects in Tgfbr1
Mutant Growth Plate Cartilage. We performed histological analy-
ses to investigate mechanisms underlying the Tgfbr1Col2 phenotype.
Fig. 1. Skeletal malformation in Tgfbr1Col2 mice. (A–D) Cleared skeletal
preparations of E12.5, E13.5, E16.5, and E18.5 control and Tgfbr1 mutant em-
bryos. Lateral views of littermates demonstrating that spine malformations can
be detected in Tgfbr1mutants by E13.5 and become more severe at E18.5 (n =
5). Blue shows Alcian blue staining of cartilage. Red shows Alizarin red staining
of bone. Control = Tgfbr1fx/fx;Tgfbr1Col2 = Tgfbr1fx/fx;Col2a1Cre; black arrows in
A–C denote the reduced sizes of cervical vertebral elements in mutants; black
arrowheads in A–D denote the smaller, flatter lumbar vertebral bodies in
Tgfbr1Col2mice. Green arrow in C denotes the locations of kinks in rib elements.
Green arrowhead in C denotes the shortened sternebrae in Tgfbr1mutants. (E–H)
Lateral views of E16.5 (E and F) and E18.5 (G and H) forelimbs (E and G) and
hindlimbs (F and H), demonstrating the short humerus, femur, and tibia in
Tgfbr1 mutants compared with control littermates (n = 5). Black arrowhead
points out the malformation of scapulae; black arrow denotes the dislocation
of elbow joints; green arrow points out the small tibial condyles in E18.5 Tgfbr1
mutant mice. (I) Magnified views of the defects in E18.5 scapulae and elbow
joints in Tgfbr1 mutant mice shown in G. Black arrowhead points out the
malformation of scapulae and black arrow denotes the dislocation of elbow
joints in Tgfbr1 mutant mice. (J) Magnified views of the defects in E18.5 knee
joints in Tgfbr1mutant mice shown in H. Black and blue double-headed arrows
measure the length of control and Tgfbr1 mutant femoral cartilage, re-
spectively. Green and white bars measure the widths of the neck of femoral
cartilage of control and Tgfbr1 mutants, respectively. Red and yellow bars
measure the widths of the neck of tibial cartilage of control and Tgfbr1 mu-
tants, respectively. The white arrow points out the flattened posterior tibial
condyle in mutants; the green arrow shows the smaller anterior tibial condyle
in mutants. (K and L) Quantification of the total lengths of tibiae in E16.5 and
E18.5 control and Tgfbr1 mutant embryos. n = 5 mice. Columns indicate av-
erage length of cartilage elements. Error bar shows SD. *P < 0.05; Student’s 2-
tailed t test. (M and N) Quantification of the length of tibial and femoral
cartilages at knee joints in E18.5 control and Tgfbr1 mutant embryos. n =
5 mice. Columns indicate average length of cartilage elements. Error bar shows
SD. *P < 0.05; Student’s 2-tailed t test. (O and P) Quantification of the widths of
tibial and femoral cartilages at knee joints in E18.5 control and Tgfbr1 mutant
embryos. n = 5 mice, Columns indicate average length of cartilage elements.
Error bar shows SD. *P < 0.05; Student’s 2-tailed t test.
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The RZ is a sparsely dividing reservoir of cells that gives rise
to the actively proliferating cells of the CZ (1). Tgfbr1Col2
mice have shorter RZs and longer CZs (Fig. 2 A and B) at
E16.5 and E18.5 (Fig. 2 C, D, G, and H), although the lengths of
HZ and the total growth plate do not differ in Tgfbr1Col2 and
control littermate mice (Fig. 2 E, F, I, and J). Immunostaining for
proliferating cell nuclear antigen (PCNA) revealed that levels of
proliferation are higher in the CZ and RZ in Tgfbr1Col2 mice
(Fig. 2 K and L). These results suggest that loss of Tgfbr1 leads to
premature conversion of slowly dividing RZ cells into rapidly
proliferating CZ cells and depletion of the RZ (Fig. 2 K and L).
Terminal deoxynucleotidyltransferase deoxyuridine triphosphate
nick-end labeling (TUNEL) assay was performed to test whether
increased apoptosis also contributes to the shorter RZ and
smaller tibial condyles in Tgfbr1Col2 mice. No TUNEL-positive
cells are seen in Tgfbr1Col2 RZ and in condyles; strong TUNEL
staining is present only in the terminal HZ and adjacent peri-
chondrium (Fig. 2M). No differences are observed in Tgfbr1Col2
and control littermate mice in these areas (Fig. 2N).
Increased BMP Signaling in Growth Plate Cartilage. TGFβRI can
trigger multiple downstream pathways, including SMAD2/3-mediated
canonical signaling, TAK1-mediated noncanonical signaling, and
SMAD1/5/8-mediated BMP signaling (8, 9, 20, 21). Immunostain-
ing showed that there is a significant decrease in the percentage of
p-SMAD2/3–positive cells in Tgfbr1Col2 growth plates (Fig. 3 A and
B). However, Smad2 and Smad3 mutants do not have any of the
defects seen in Tgfbr1Col2 growth plates (13), suggesting that the
decrease in p-SMAD2/3 is not a major contributor to the Tgfbr1Col2
phenotype. Similarly, TAK1 is required in growth plate cartilage to
activate proliferation (22). In palatal mesenchyme, TGFβ2 activates
TAK1 independently of TGFβRII through TGFβRI (15). However,
immunostaining revealed no difference in pTAK1 expression in
Tgfbr1Col2 mice (Fig. 3 C and D).
Multiple studies indicate that BMP signaling triggers pro-
liferation of RZ and CZ chondrocytes (23–25). Because the
growth plate defects in Tgfbr1Col2 mice are consistent with ele-
vated BMP signaling and cannot be explained by decreased ac-
tivation of TGFβ pathways, we considered the possibility that
BMP signaling is altered. Immunostaining for pSMAD1/5/8
revealed an increased percentage of pSMAD1/5/8-positive cells
in the RZ and CZ of Tgfbr1Col2 mice (Fig. 3 E and F). The in-
creased pSMAD1/5/8 levels do not arise through increased
mRNA expression of key BMP, TGFβ, or GDF ligands, BMP
type I or type II receptors, the BMP inhibitor NOGGIN, or the
BMP signaling mediators SMAD1, SMAD5, and SMAD8 (SI
Appendix, Fig. S2).
Loss of Acvrl1 Rescues Growth Plate Defects in Tgfbr1Col2 Mutant
Mice. The above findings indicated that TGFβRI acts to inhibit
BMP signaling in growth plate cartilage. In considering potential
mechanisms, we focused on the type I BMP receptor ACVRL1
(ALK1). ACVRL1 has been studied almost exclusively in the
context of the vasculature, because heterozygous loss-of-function
mutations in Acvrl1 lead to hereditary hemorrhagic telangiecta-
sia in humans (26). However, Acvrl1 is expressed in articular
cartilage (27, 28). ACVRL1 can interact physically with TGFβRI
and TGFβRII to enable TGFβ ligands to activate BMP signaling
(21). According to this model, loss of TGFβRI would lead to
decreased BMP signaling, opposite to the elevated BMP signaling
observed in Tgfbr1Col2 growth plates. We therefore speculated that
an alternative function for TGFβRI could be to inhibit BMP
signaling through ACVRL1. This might occur if TGFβRI prevents
formation of highly active (ACVRL1/ACTRIIA or ACVR1/
ACTRIIB) complexes by sequestering ACVRL1 into less active
complexes containing TGFβRI.
ACVRL1 is expressed in all zones of the growth plate (Fig.
4A). To test the role of ACVRL1 in cartilage and whether there
is a genetic interaction between Tgfbr1 and Acvrl1, we generated
Acvrl1f/f;Col2-Cre (Acvrl1Col2) and Acvrl1/Tgfbr1 double-mutant
Acvrl1f/f;Acvrl1f/f;Col2-Cre (Acvrl1/Tgfbr1Col2) mice. Cartilage-
specific deletion of ACVRL1 was confirmed by immunohisto-
chemistry (IHC) (Fig. 4B). Acvrl1Col2 mice are apparently normal
at E18.5 (Fig. 4 C and D). Histological analysis showed that
Acvrl1Col2 mice have normal growth plates (Fig. 4 G and H), and
no changes in pSMAD1/5/8 levels were detected (Fig. 4 K and
L). Strikingly, however, simultaneous loss of Acvrl1 and Tgfbr1
rescues most of the skeletal defects seen in Tgfbr1Col2 mice (Fig.
4 E and F). The length of the CZ (Fig. 4 G, I, and J) and
Fig. 2. Increased proliferation in Tgfbr1 mutant growth plates. (A and B)
Sections of E16.5 and E18.5 proximal tibias were stained with safranin O,
showing reduced RZ and expanded CZ. Heights of different growth plate zones
are indicated by double arrows, and the zone boundaries are marked by lines.
Blue dashed line is the demarcation between the CZ and pre-HZ. All images are
aligned to this boundary. Top yellow lines demarcate the approximate bound-
ary between the RZ and CZ. Bottom yellow lines demarcate the boundary be-
tween the HZ and zone of ossification (chondro-osseous junction). Yellow
double-headed arrows indicate the extent of the CZ. Green double-headed
arrows demarcate the extent of the RZ. Blue double-headed arrows demarcate
the extent of the HZ. Three litters containing mice of all of the genotypes
shown in the figures were examined. At least 5 mice per genotype were ex-
amined. The images shown are from littermates. Black arrow highlights ab-
sence of the PCL enthesis. (C–J) Quantification of the lengths of different zones
and whole growth plates. Data are expressed as means of length + SD (n =
5 mice). *P < 0.05; Student’s 2-tailed t test compared with control Tgfbr1fx/fx.
(K) Immunostaining for PCNA (red) in E16.5 proximal tibia. RZ (green brackets)
and CZ (yellow brackets). All mice are littermates. (L) Quantitation of the
percentage of PCNA-positive cells in distinct zones. The percentage of PCNA-
positive cells in the RZ and CZ was quantified. Data are expressed as means of
percent PCNA-positive + SD (n = 4 mice). *P < 0.05 compared with control
Tgfbr1fx/fx mice. (M) TUNEL (green) staining in E16.5 proximal tibia. All mice
are littermates. White arrowheads point to perichondrium. Red dotted lines
indicate chondro-osseous junction. (N) Quantitation of the percentage of
TUNEL-positive cells at chondro-osseous junctions. Data are expressed as
means of percent TUNEL-positive + SD (n = 4 mice). There are no significant
differences between Tgfbr1Col2 and control Tgfbr1fx/fx mice.
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pSMAD1/5/8 levels (Fig. 4 K, M, and N) are restored to normal
in Acvrl1/Tgfbr1Col2 mice. However, the rescue of Tgfbr1Col2 de-
fects is not complete. Vertebral bodies remain smaller than con-
trol littermates in Acvrl1/Tgfbr1Col2 mice (Fig. 4 C, E, and F;
arrowheads), and the enthesis defects are not fully rescued (Fig. 4
G, I, and J; arrows). These defects could reflect a role for TGFβRI
in transducing TGFβ pathways, and/or interactions between
TGFβRI and type I BMP receptors other than ACVRL1 in these
regions. Nonetheless, these results demonstrate that Acvrl1 is not
necessary for growth plate formation, but interacts genetically with
Tgfbr1, and that TGFβRI antagonizes ACVRL1 function in the
growth plate.
TGFβRI Associates with ACVRL1 and ACTRIIB to Inhibit ACVRL1/
ACTRIIB Complex Formation. The genetic studies demonstrated
that a key function for TGFβRI is to constrain ACVRL1 sig-
naling in the growth plate. ACVRL1 normally complexes with
ACTRIIA/B to transduce BMP9/10-activated SMAD1/5/8 BMP
signaling (29). TGFβRI complexes with ACTRIIA/B transduce
GDF8/11-activated SMAD2/3 TGFβ signals (16, 18). Therefore,
competition between ACVRL1 and TGFβRI for ACTRIIA and/
or ACTRIIB provides a potential explanation for the elevated
BMP signaling in Tgfbr1Col2 mice and its rescue in Acvrl1/Tgfbr1
double mutants. We performed coimmunoprecipitation (co-IP)
in ATDC5 chondrocytes under serum-free conditions to identify
endogenous TGFβRI interactions with type I and type II BMP
receptors. Among the type I BMP receptors, TGFβRI associates
primarily with ACVRL1 (Fig. 5 A and B). A low level of asso-
ciation of TGFβRI with ACVR1, the type I receptor most closely
related structurally to ACVRL1 (8), was detected; almost no
association with BMPR1A or BMPR1B was found. Proximity
ligation assay (PLA) confirmed that the observed interaction
between TGFβRI and ACVRL1 occurs in vivo (SI Appendix, Fig.
S5). Thus, the genetic interaction between ACVRL1 and
TGFβRI is correlated with a physical interaction between these
receptors in chondrocytes. We next considered interactions with
type II receptors. We focused on TGFβRII because TGFβRI/
TGFβRII complexes transduce canonical signaling by TGFβs
1 to 3, and on ACTRIIA and ACTRIIB because these type II
receptors can complex with either ACVRL1 or TGFβRI (3, 16,
18, 29). Among the tested type II receptors, TGFβRI associates
exclusively with ACTRIIB under serum-free conditions (Fig. 5 C
and D). The lack of association between TGFβRI and TGFβRII
is consistent with the lack of a growth plate phenotype in
Tgfbr2Col2 mice (12).
Fig. 3. Increased BMP signaling activity in Tgfbr1 mutant growth plates. All
images are E16.5 proximal tibias. Quantification data are expressed as means +
SD (n = 3 mice). *P < 0.05; Student’s 2-tailed t test. (A and B) Immunos-
taining for phosphorylated SMAD2 and SMAD3 showing decreased protein
levels in Tgfbr1 mutant growth plates. (B) Quantification of pSMAD2/3 pro-
tein level in posterior condyles (yellow boxes), anterior condyles (white
boxes), and CZs (red boxes) of growth plate. (C and D) Immunostaining for
phosphorylated TAK1 (pTAK1) showing no change of expression levels in
Tgfbr1mutant growth plates. (D) Quantitation of pTAK1 protein level in the
posterior condyles (yellow boxes), anterior condyles (white boxes), and CZs (red
boxes) of growth plate. (E and F) Immunostaining for phospho-SMAD1/5/8
protein showing increase levels of activated BMP signaling in Tgfbr1Col2
growth plates. (F) Quantitation of pSMAD1/5/8 protein level in the posterior
condyles (yellow boxes), anterior condyles (white boxes), and CZs (red boxes)
of growth plate.
Fig. 4. Rescue of the Tgfbr1 mutant phenotype in Acvrl1/Tgfbr1Col2 double
mutants. All images are E18.5. (A and B) Immunofluorescent staining showing
ACVRL1 protein presence in proximal tibial growth plates of control mice (A)
and lack of staining in Acvrl1mutant mice (B) verifies antibody specificity and
cartilage-specific knockout. Red, α-ACVRL1 staining; blue, DAPI. (C–F) Skeletal
preps showing no alterations in Acvrl1 Col2 mice, and rescue of the
chondrodysplasia in Acvrl1/Tgfbr1Col2 mice compared with Tgfbr1Col2 mice. Arrow-
heads point to the vertebral body (VB); note that there are no defects in
Acvrl1Col2 VB, but both Acvrl1/Tgfbr1Col2 and Tgfbr1Col2 mice have smaller VB
compared with control mice. n = 5/genotype. (G–J) Sections through proximal
tibia growth plates showing restoration of the highs of the CZ and the sizes of
posterior condyle in Acvrl1/Tgfbr1Col2 mice. Blue brackets indicate the high of
CZ. Black arrow points to the rescued tibia condyle in Acvrl1/Tgfbr1Col2 mice.
Blue arrow points to the defective of posterior tibial condyle in Acvrl1/
Tgfbr1Col2mice. n = 3/genotype. (K–N) pSMAD1/5/8 levels appear to be restored
to normal in Acvrl1/Tgfbr1Col2 mice. n = 3/genotype.
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The association of TGFβRI with ACTRIIB in chondrocytes is
consistent with potential competition between ACVRL1 and
TGFβRI for this type II receptor. We generated Tgfbr1 mutant
ATDC5 cells (Tgfbr1Δ/Δ) using Crispr-Cas9 systems to test this
possibility. The removal of TGFβRI was confirmed by Western
blot (Fig. 5 E and F). Elevated pSMAD1/5/8 levels were seen
in Tgfbr1Δ/Δ cells even under serum-free conditions (Fig. 5 E and
G), confirming that loss of TGFβRI leads to elevated BMP
signaling in chondrocytes. Co-IP assays were performed to de-
termine how loss of TGFβRI impacts association of ACVRL1
with type II receptors. In control cells, ACVRL1 associates
primarily with ACTRIIA (Fig. 5 H and I). In Tgfbr1Δ/Δ cells,
ACVRL1 associates with both ACTRIIA and ACTRIIB (Fig.
5H). Thus, loss of TGFβRI significantly increases the interaction
of ACVRL1 with ACTRIIB (Fig. 5I). The increased formation
of ACVRL1/ACTRIIB complexes is not caused by increased
ACTRIIB protein levels because there is a similar level of input
of ACTRIIB between control and Tgfbr1Δ/Δ cells (Fig. 5H). There
is no change in ACVRL1/TGFβRII or ACVRL1/ACTRIIA com-
plexes in Tgfbr1Δ/Δ cells compared with the control (Fig. 5I).
Furthermore, there is a significant increase in ACVRL1/ACTRIIB
interaction in Tgfbr1Δ/Δ cells compared with control cells after nor-
malization to ACVRL1 input levels (Fig. 5 J and K). No changes in
levels of ACVRL1/TGFβRII or ACVRL1/ACTRIIA complex for-
mation were seen in Tgfbr1Δ/Δ cells (Fig. 5 J and K), suggesting that
the increased formation of ACVRL1/ACTRIIB complexes is re-
sponsible for the elevated pSMAD1/5/8 levels in Tgfbr1Δ/Δ cells.
Loss of TGFβRI Increases Basal BMP Activity and BMP9 Responsiveness
in Chondrocytes. The above findings demonstrated increased
formation of ACVRL1/ACTRIIB complexes in Tgfbr1Δ/Δ cells.
To test whether the ACVRL1/ACTRIIB complex has a specific
function in mediating elevated BMP signaling in Tgfbr1Δ/Δ
cells, cells were treated with BMP9, which acts exclusively through
ACVRL1 or ACVR1 complexed to ACTRIIA or ACTRIIB, but
shows significantly higher affinity for ACTRIIB than for ACTRIIA
(29). TGFβ1 and BMP2 were used as controls because TGFβ1 can
trigger BMP signaling through ACVRL1/TGFβRI/TGFβRII com-
plexes (27). BMP2 activates BMPR1A and BMPR1B, and to a
lesser extent ACVR1, but not ACVRL1 (8, 30–32). 12×SBE-Luc
reporter assays showed that Tgfbr1Δ/Δ cells have higher basal BMP
activity (2×) than control cells (1×), and increased responsiveness
to BMP9 (5.8× vs. 3.3×) (significance confirmed by ANOVA and
t test) (Fig. 6A). In contrast, responsiveness to BMP2 was slightly
lower in Tgfbr1Δ/Δ (2.6×) compared with control cells (3.2×) (no
significance by ANOVA and t test) (Fig. 7A). Consistent with the
previously demonstrated requirement for TGFβRI in TGFβ-
mediated BMP pathway activation (21), TGFβ1 stimulates BMP
signaling in control, but not in Tgfbr1Δ/Δ cells. Taken together, these
results indicate that loss of TGFβRI increases sensitivity to BMP9.
Since the affinity of BMP9 for ACVRL1/ACTRIIB complexes is
several orders of magnitude higher than for ACVRL1/ACTRIIA
complexes (29), our results suggest that the increased formation of
ACVRL1/ACTRIIB receptor complexes (Fig. 5) may be responsible
for the increased responsiveness to BMP9 in Tgfbr1Δ/Δ cells.
As discussed, basal BMP activity is elevated in Tgfbr1Δ/Δ ATDC5
cells even under serum-free conditions. To test whether the ele-
vated basal activity is due to production of an endogenous ligand,
the BMP inhibitor NOGGIN (blocks BMPs 2, 4, 5, and 7, and
GDFs 5 to 7) (33) was added to the cells followed by reporter
assay. The elevated basal BMP activity in Tgfbr1Δ/Δ cells is not
affected by NOGGIN; NOGGIN activity was confirmed by its
ability to block the effects of recombinant BMP2 activity (Fig. 6B).
NOGGIN does not inhibit BMPs 9 or 10, the ligands for ACVRL1
(34). To test whether the elevated basal BMP activity in Tgfbr1Δ/Δ
cells is due to production of BMP9 or BMP10 and signaling through
ACVRL1/ACTRIIB complexes, anti-BMP9 antibody, ACVRL1-Fc,
or ACTRIIB-Fc was added to the cells. Anti-BMP9 antibody blocks
BMP9 function (35, 36). ACVRL1-Fc and ACTRIIB-Fc bind to
BMP9 and BMP10 (29, 37). While anti-BMP9 antibody, ACVRL1-
Fc and ACTRIIB-Fc inhibit the effects of exogenous BMP9, they do
not affect the elevated basal activity (Fig. 6 C–E). These results
demonstrate that the increased BMP output is not due to increased
Fig. 5. TGFβRI associates with ACVRL1 and ACTRIIB to block ACVRL1/
ACTRIIB complex formation. (A) TGFβRI associates most with ACVRL1. Lysates
prepared from ATDC5 cells were subjected to IP with an anti-TGFβRI anti-
body cross-linked to magnetic beads. Immunoprecipitated proteins were
then probed with anti-ACVRL1, anti-ACVR1, anti-BMPR1A, and anti-BMPR1B
antibodies. (B) Quantification of protein levels shown in A. Three biological
replicates were analyzed. The average input protein level is normalized to 1.
Immunoprecipitated protein level (IP-TGFβRI) was normalized using input
and plotted relative to input + SD (n = 3). Significance was established using
2-way ANOVA and t test. *P < 0.013. (C) Of the tested type II BMP receptors,
TGFβRI associates almost exclusively with ACTRIIB. Immunoprecipitated
proteins were probed with anti-TGFβRII, anti-ACTRIIA, and anti-ACTRIIB
antibodies. Note that ACTRIIB, but not TGFβRII or ACTRIIA, could be coim-
munoprecipitated with TGFβRI. (D) Quantification of protein levels shown in
C. Three biological replicates were analyzed as described in B. *P < 0.017. (E)
Western blot images confirm that TGFβRI protein is deleted by Crispr-cas9 in
Tgfbr1mutant (Tgfbr1△/△) ATDC5 cells, and that these cells exhibit elevated
basal pSMAD1/5/8 levels. (F and G) The Western blot images of TGFβRI (F)
and pSMAD1/5/8 levels (G) were quantified using ImageJ. Values of protein
level were normalized using GAPDH and are plotted relative to control + SD
(n = 3 biological replicates). Significance was established using Student’s 2-
tailed t test. *P < 0.05. (H) Lysates from control or Tgfbr1△/△ cells were
subjected to IP with an anti-ACVRL1 antibody. Immunoprecipitated proteins
were then probed with anti-TGFβRII, anti-ACTRIIA, and anti-ACTRIIB anti-
bodies. In control cells, ACVRL1 associates with ACTRIIA. In Tgfbr1△/△cells,
ACVRL1 associates with both ACTRIIA and ACTRIIB. (I) Quantification of
protein levels shown in E. Three biological replicates were analyzed.
Immunoprecipitated protein level was normalized using input and plotted
relative to input + SD (n = 3). Significance was established using Student’s 2-
tailed t test. *P < 0.01. Note that there is a significant increase of ACTRIIB/
ACVRL1 association in Tgfbr1△/△ cells compared with control cells. (J) Ly-
sates from control or Tgfbr1△/△ cells were subjected to IP with an anti-
TGFβRII, anti-ACTRIIA, or anti-ACTRIIB antibody. Immunoprecipitated pro-
teins were then probed with an anti-ACVRL1 antibody. In control cells,
ACVRL1 associates with ACTRIIA. In Tgfbr1△/△ cells, ACVRL1 associates with
both ACTRIIA and ACTRIIB. (K) Quantification of protein levels shown in G.
Three biological replicates were analyzed as described in I. *P < 0.05. Note
that there is a significant increase in ACTRIIB/ACVRL1 association in
Tgfbr1△/△ cells compared with control cells.
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expression of ligands inhibited by NOGGIN (BMPs 2, 4, 5, and 7, or
GDFs 5 to 7), or BMPs 9 and 10.
Anti-ACVRL1 antibody was used to test whether the in-
creased basal and BMP9-induced BMP signaling is mediated
directly by ACVRL1 in Tgfbr1Δ/Δ cells. In control cells, anti-
ACVRL1 has no impact (Fig. 6 F, columns 3 and 4). However,
in Tgfbr1Δ/Δ cells, anti-ACVRL1 blocks both elevated basal BMP
activity and responsiveness to BMP9 (Fig. 6 F, columns 7 and 8).
The basis for the lack of effect of anti-ACVRL1 in control cells is
unclear but may be a consequence of sequestration of ACVRL1
by TGFβRI (Fig. 5) into inactive signaling complexes. According
to this scenario, the observed responsiveness to BMP9 in control
cells may be mediated by ACVR1 rather than ACVRL1. None-
theless, these results show that ACVRL1 is responsible for in-
creased BMP activity in Tgfbr1Δ/Δ cells. To confirm this, the kinase
domain in ACVRL1 was mutated by replacing threonine-196 with
valine using Crispr-Cas9 in Tgfbr1Δ/Δ cells. Loss of ACVRL1 kinase
activity rescues both basal BMP activity and responsiveness to
BMP9 in Acvrl1KKD/Tgfbr1Δ/Δ cells (Fig. 6G), confirming that ac-
tivation of ACVRL1 causes increased BMP signaling in Tgfbr1Δ/Δ
cells.
Finally, we tested the potential involvement of ACTRIIB in
the increased basal and BMP9-induced BMP signaling in
Tgfbr1Δ/Δ cells. In control cells, anti-ACTRIIB has no impact on
basal BMP signaling but deceases BMP9-induced activity (Fig. 6
H, columns 3 and 4). In Tgfbr1Δ/Δ cells, anti-ACTRIIB blocks
elevated basal BMP activity (Fig. 6 H, columns 1 and 7). In
addition, anti-ACTRIIB blocks most (69%) of BMP9-induced
BMP activity (Fig. 6 H, columns 6 and 8). The remaining re-
sponsiveness to BMP9 is higher than the control level (Fig. 6 H,
Fig. 6. Loss of TGFβRI leads to elevated basal BMP activity and BMP9 responsiveness in chondrocytes. Cells were transfected with 12×SBE-Luc reporter (77)
and Renilla luciferase control reporter. Relative 12×SBE-Luc activity shows the normalized level of 12×SBE-Luc/Renilla Luc. Assays were repeated 2 times. n =
3/technical repeats in each assay. Error bars show SE. Significance was established using 2-way ANOVA and t test. *P < 0.05/n (n = number of groups). (A)
Elevated basal BMP activity and BMP9 responsiveness in chondrocytes. The basal BMP activity in Tgfbr1Δ/Δ cells is more than 2-fold higher than in control cells
(columns 1 and 5). TGFβ1 treatment (2 ng/mL) increases BMP activity in control cells but does not affect Tgfbr1Δ/Δ cells (columns 2 and 6). BMP2 (100 ng/mL)
and BMP9 (100 ng/mL) have similar activities in control cells at the tested concentrations (columns 3 and 4). BMP9 induces higher BMP activity than BMP2 in
Tgfbr1Δ/Δ cells (columns 7 and 8). (B) NOGGIN does not block elevated basal BMP activity in Tgfbr1Δ/Δ cells. Elevated BMP activity in Tgfbr1Δ/Δ cells compared
with control cells (columns 1 and 5). BMP2 activity in control and Tgfbr1Δ/Δ cells (columns 2 and 6). NOGGIN inhibits BMP2 activity in both control and Tgfbr1Δ/Δ
cells (columns 3 and 4, and columns 7 and 8). NOGGIN does not block elevated basal BMP activity in Tgfbr1Δ/Δ cells (columns 5 and 8). (C) BMP9 antibody does
not block elevated basal BMP activity in Tgfbr1Δ/Δ cells. BMP reporter activity is activated by BMP9 in control ATDC5 cells (columns 1 and 2). α-BMP9 antibody
blocks exogenous BMP9 action in control and Tgfbr1Δ/Δ cells (columns 3 and 7). Tgfbr1Δ/Δ cells exhibit elevated basal BMP activity (columns 1 and 5). Tgfbr1Δ/Δ
cells respond to BMP9 (columns 5 and 6). α-BMP9 antibody has no effect on elevated basal BMP activity in Tgfbr1Δ/Δ cells (columns 5 and 8). (D) ACVRL1-Fc does
not block elevated basal BMP activity in Tgfbr1Δ/Δ cells. BMP reporter activity is activated by BMP9 in control ATDC5 cells (columns 1 and 2). ACVRL1-Fc blocks
exogenous BMP9 action in control and Tgfbr1Δ/Δ cells (columns 3 and 7). Tgfbr1Δ/Δ cells exhibit elevated basal BMP activity (columns 1 and 5). Tgfbr1Δ/Δ cells
respond to BMP9 (columns 5 and 6). ACVRL1-Fc has no effect on elevated basal BMP activity in Tgfbr1Δ/Δ cells (columns 5 and 8). (E) ACTRIIB-Fc does not block
elevated basal BMP activity in Tgfbr1Δ/Δ cells. BMP reporter activity is activated by BMP9 in control ATDC5 cells (columns 1 and 2). ACTRIIB-Fc blocks exogenous
BMP9 action in control and Tgfbr1Δ/Δ cells (columns 3 and 7). Tgfbr1Δ/Δ cells exhibit elevated basal BMP activity (columns 1 and 5). Tgfbr1Δ/Δ cells respond to
BMP9 (columns 5 and 6). ACVRL1-Fc has no effect on elevated basal BMP activity in Tgfbr1Δ/Δ cells (columns 5 and 8). (F) ACVRL1 antibody blocks elevated
basal BMP activity in Tgfbr1Δ/Δ cells. BMP reporter activity is activated by BMP9 in control ATDC5 cells (columns 1 and 2). Anti-ACVRL1 antibody does not block
BMP9 action in control cells (columns 2 and 4). Tgfbr1Δ/Δ cells exhibit elevated basal BMP activity (columns 1 and 5). Anti-ACVRL1 antibody blocks elevated
basal BMP activity in Tgfbr1Δ/Δ cells (columns 5 and 7). Anti-ACVRL1 antibody restores BMP9 activity to control level in Tgfbr1Δ/Δ cells (columns 2, 4, and 8). (G)
Loss of ACVRL1 kinase activity restores BMP signaling to normal level in the Tgfbr1Δ/Δ cells. Elevated BMP activity in Tgfbr1Δ/Δ cells compared with control cells
(columns 1 and 3). Mutation of threonine-196 to valine near the canonical start of the ACVRL1 kinase domain (Acvrl1KD) using Crispr-Cas9 system in the
Tgfbr1Δ/Δ cells (column 5); BMP activity in Tgfbr1/Acvrl1 double-mutant cells is restored to normal (columns 1 and 5). BMP9 activity in control and Tgfbr1Δ/Δ
cells (columns 2 and 4). BMP9 activity in Tgfbr1/Acvrl1 double-mutant cells is lower than Tgfbr1Δ/Δ cells and restored to control levels (columns 2, 4, and 6). (H)
Anti-ACTRIIB antibody blocks elevated basal BMP activity in Tgfbr1Δ/Δ cells. BMP reporter activity is activated by BMP9 in control ATDC5 cells (columns 1 and 2).
Anti-ACTRIIB antibody deceases BMP9 action in control cells (columns 2 and 4). Tgfbr1Δ/Δ cells exhibit elevated basal BMP activity (columns 1 and 5). Anti-
ACTRIIB antibody blocks elevated basal BMP activity in Tgfbr1Δ/Δ cells (columns 5 and 7). Anti-ACTRIIB antibody decreases BMP9 activity by 2-fold in Tgfbr1Δ/Δ
cells (columns 6 and 8) but does not completely restore BMP9 activity to control levels (columns 4 and 8).
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columns 4 and 8). It is unclear whether this is due to only partial
blockade of ACTRIIB by the antibody, or to involvement of
other type II BMP receptors. Nonetheless, the results indicate
that ACTRIIB plays the major role in elevated basal activity and
BMP9 responsiveness in Tgfbr1Δ/Δ cells, supporting the hypoth-
esis that loss of TGFβRI increases BMP signaling through in-
creased formation of ACVRL1/ACTRIIB complexes.
BMP9 and ACVRL1/ACTRIIB Complexes Are Present in Cartilage of
Tgfbr1Col2 Mice. The finding that ACVRL1 mediates elevated
BMP signaling in Tgfbr1-deficient chondrocytes was unexpected
because neither ACVRL1 nor its ligands BMP9 and BMP10
have been implicated in growth plate formation. BMP9 and
BMP10 are not expressed in normal cartilage (38, 39). In ac-
cordance, we did not detect Bmp9 and Bmp10 RNA in control or
Tgfbr1Col2 cartilage by RT-PCR and qPCR (SI Appendix, Fig.
S2). However, BMP9 and BMP10 circulate in blood (2 to 6 and
0.2 to 2 ng/mL, respectively) in mice (40, 41) at high enough
levels to activate ACVRL1. IHC was performed to test whether
BMP9 from the circulation or elsewhere can penetrate growth
plate cartilage. BMP9 is detected in control and Tgfbr1Col2
tissues, with high levels in blood vessels, bone, and muscle, and low
levels in cartilage (Fig. 7 A and B); the specificity of the BMP9
antibody is confirmed by the absence of staining in Bmp9−/− tissue
(37) (Fig. 7C). These results suggest that BMP9 in carti-
lage may defuse from nearby vascularized tissues and can po-
tentially activate ACVRL1 in cartilage.
Our in vitro data showed an increase in ACVRL1/ACTRIIB
complex formation in Tgfbr1Δ/Δ cells, and that these complexes
cause elevated BMP activity in Tgfbr1Δ/Δ cells. We therefore
tested whether we could detect increased ACVRL1/ACTRIIB
complex formation in cartilage of Tgfbr1Col2 mice using PLA.
These complexes are rarely detected in control cartilage but are
present in Tgfbr1Col2 cartilage (SI Appendix, Fig. S3 A–D).
Discussion
The studies described here demonstrate that TGFβRI is an es-
sential regulator of growth plate chondrocyte proliferation and
differentiation. However, TGFβRI, the requisite type I receptor
for signal transduction by TGFβs 1 to 3, does not exert its pri-
mary function in growth plate chondrocytes via activation of
TGFβ pathways. Several lines of evidence support this conclu-
sion. First, the strong Tgfbr1Col2 phenotype contrasts with the
near absence of growth plate phenotypes in embryos and
neonates of Tgfbr2Col2 or Smad2Col2;Smad3−/− mice (12, 13).
Second, the Tgfbr1Col2 phenotype is consistent with elevated
BMP activity: Tgfbr1Col2 mice have a shorter RZ and a longer CZ,
associated with an increased proportion of proliferating cells in
both regions. This is a hallmark of BMP signaling in chondrocytes
(6, 42, 43). Third, pSMAD1/5/8 levels are elevated in Tgfbr1Col2
growth plates, and SMADs 1/5/8 play essential roles in activating
chondrocyte proliferation in vivo (42). Fourth, pSMAD1/5/8
levels and the majority of the growth plate defects are restored to
normal in Acvrl1/Tgfbr1Col2 mice.
In addition to the appendicular growth plate phenotype
documented here, Tgfbr1Col2 mice exhibit axial defects. The axial
phenotype appears to be similar to that in Tgfbr1Dermo1 mice (19).
Tgfbr1 is highly expressed in intervertebral discs and perichon-
drium (19). Col2Cre is expressed in the sclerotome before the
specification of separate lineages for vertebral cartilage and in-
tervertebral discs (44). Since both Col2Cre and Dermo1Cre
would target these tissues, the axial defects in Tgfbr1Col2 mice
most likely arise through a role for TGFβRI in perichondrium
and intervertebral discs. Additional studies employing other ge-
netic models would be needed to define cartilage-intrinsic roles
for TGFβRI in vertebral elements. Furthermore, TGFβRI is
more widely expressed in posterior condylar tibial cartilage than
in anterior condylar tibial cartilage (SI Appendix, Fig. S1 F and
I). Consistently, the posterior condyle is smaller than the anterior
condyle in Tgfbr1Col2 mice. These findings establish Tgfbr1 as a
gene that regulates the differential development of condyles.
Evidence for a role for TGFβ signaling in the formation of
tendon and ligament insertions has been presented previously.
Tgfbr2Prx1 mice lack tibial medial condyle and deltoid tuberosity
formation (45). However, Tgfbr2Col2 mice do not show such phe-
notypes (12), suggesting that the defects in Tgfbr2Prx1 mice are not
caused by cells derived from committed chondrocytes. The
Tgfbr1Col2 defects are distinct from those in Tgfbr2Prx1 mice in that
Tgfbr1Col2 mice have both anterior and posterior condyle defects
instead of absence of the medial condyle, and Tgfbr1Col2mice have
normal tuberosities. In addition, none of the defects seen in
Tgfbr1Col2 mice is found in Tgfbr2Col2 mice (12). This suggests that
Tgfbr1 regulates posterior and anterior condyle formation in
cartilage, but probably not through canonical TGFβ signaling.
Scx+;Sox9+ cells in the TGFβRI-expressing regions of the condyles
give rise to ligaments and the ligamentous junction (46). Future
studies would thus be of interest to elucidate the role of TGFβRI
in the differential development of condyles, ligaments, and asso-
ciated structures, and to understand the basis for the differing
condylar phenotypes in Tgfbr1Col2 and Tgfbr2Col2 mice.
Our studies unveiled that the excess BMP signaling in
Tgfbr1Col2 mice is mediated by ACVRL1. A role for TGFβRI as
an inhibitor of ACVRL1 function has not been reported pre-
viously. Little is known about ACVRL1 function in cartilage, but
TGFβRI and ACVRL1 have opposing functions in chondrocytes
in vitro (28). The absence of a discernable phenotype in Acvrl1Col2
mice indicates that this receptor is dispensable for cartilage devel-
opment. The loss of TGFβR1 leads to a deleterious gain of function
of ACVRL1 signaling in cartilage. This raises the question of the
normal function of Acvrl1 in cartilage. Although we have not de-
tected an obvious phenotype in Acvrl1Col2 mice at birth, we cannot
rule out subtle defects. Examination of adult mice may reveal such
changes. Furthermore, it is possible that loss of ACVRL1 is com-
pensated for by the closely related type I BMP receptor ACVR1
(ALK2). Like ACVRL1, ACVR1 is activated by BMPs 9 and 10 (8).
Acvr1Col2 mice are viable and exhibit only mild appendicular defects
(47). Removing both Acvrl1 and Acvr1 in cartilage might provide
evidence for compensatory roles in cartilage.
ACVRL1 has been studied most extensively in the vasculature.
Acvrl1−/− mice die at midgestation due to major defects in an-
giogenesis, and Acvrl1+/− mice and humans exhibit hereditary
hemorrhagic telangiectasia, a condition characterized by vascular
malformations (26). TGFβRI and ACVRL1 interact physically in
endothelial cells, but the functional output is different from the
one shown here in cartilage; in endothelium, ACVRL1 antagonizes
TGFβRI signaling, and TGFβRI/ACVRL1/TGFβRII complexes
activate BMP signaling (21, 28, 48), whereas in cartilage, TGFβRI
antagonizes ACVRL1. It is likely that TGFβRI and ACVRL1
Fig. 7. BMP9 protein is present in growth plate cartilage. Immunofluores-
cence analysis of WT, Tgfbr1Col2, and Bmp9−/−mice to detect the presence of
BMP9 in cartilage. WT and Tgfbr1Col2 sections are from E18.5 embryos, and
Bmp9−/− sections are from P0 newborn pups. α-BMP9 staining is red. Nuclei
are stained with DAPI (blue). n = 3 mice. (A and B) In WT and Tgfbr1Col2mice,
BMP9 protein is localized in bones as expected. However, BMP9 also presents
in the cartilage in these 2 mouse lines. Arrow points to a blood vessel. C,
cartilage; B, bone; M, muscle. (C) The specificity of anti-BMP9 antibody was
validated by using Bmp9−/−mice. No positive signal was detected in Bmp9−/−
mice. Arrow points to a blood vessel. C, cartilage; B, bone; M, muscle.
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have context-specific mutually antagonistic functions. Other
studies show that ACVRL1 can act independently of TGFβRI in
endothelial cells (49, 50). Studies in multiple cell types would be of
interest to understand the basis for the cell type-specific responses
to the TGFβRI:ACVRL1 balance.
The functions of TGFβRI and ACVRL1 in adult articular carti-
lage are unclear. Although Acvrl1Col2 mice exhibit no developmental
defects, cartilage-specific loss of ACVRL1 might impact the main-
tenance of articular cartilage in adults. ACVRL1 is expressed in
articular chondrocytes (27, 28), and the ACVRL1/TGFβRI ratio
increases in aged and osteoarthritic articular cartilage due to de-
creased TGFβRI expression (28). It will therefore be important to
test whether Acvrl1Col2 mice are resistant to age-induced osteoar-
thritis. If so, this could lead to therapeutic options for treatment of
osteoarthritis based on inhibition of ACVRL1 activity. A recent
study showed that postnatal deletion of TGFβRI in cartilage leads to
a strong osteoarthritis phenotype, suggesting direct effects in articular
cartilage (51). However, TGFβRI was deleted in young mice, and
therefore both growth plate and articular cartilage were targeted.
Nonetheless, clear alterations in gene expression were noted in ar-
ticular cartilage. Expression of Prg4, a gene expressed in superficial
zone articular chondrocytes and essential for maintenance of
boundary lubrication (52–54), is greatly reduced upon postnatal loss
of TGFβRI. It will be of great interest to elucidate the mechanism by
which TGFβRI mediates Prg4 expression (51). Prg4 can be induced
by TGFβ (51, 55, 56), but this may be independent of the canonical
pathway involving TGFβRII based on the observation that postnatal
loss of TGFβRII in cartilage is protective against osteoarthritis (57).
Taken together with studies implicating ACVRL1 in the progression
of osteoarthritis (58–60), it is likely that TGFβRI will exert some
functions in articular cartilage through direct activation of TGFβ
pathways and others via inhibition of BMP signaling through an-
tagonism of ACVRL1. Experiments to test this are underway.
None of the defects in Tgfbr1Col2 mice is seen in Tgfbr2 mutants
(12). In accordance, we found that TGFβRII interacts only mini-
mally with TGFβRI and ACVRL1 in chondrocytes; in normal car-
tilage, TGFβRI and ACVRL1 interact primarily with ACTRIIB and
ACTRIIA, respectively. TGFβRI prevents ACVRL1/ACTRIIB
complex formation, as demonstrated by the de novo formation of
these complexes in Tgfbr1Δ/Δ chondrocytes and Tgfbr1Col2 growth
plates. Our data indicate that ACVRL1/ACTRIIB complexes are
responsible for the elevated BMP signaling in Tgfbr1Col2 growth
plates (SI Appendix, Fig. S4). We speculate that elevated BMP ac-
tivity in vivo arises at least in part because ACVRL1/ACTRIIB
complexes bind BMP9 with higher affinity (300×) than ACVRL1/
ACTRIIA complexes (29). Cartilage-specific deletion and over-
expression of ACTRIIB in normal and Tgfbr1Col2 mice would pro-
vide a genetic test of this model.
BMPs 9 and 10 are the only ligands that activate ACVRL1
at physiological levels (30) and are potent inducers of
chondrogenesis in vitro (61). Tgfbr1Δ/Δ cells show greatly enhanced
sensitivity to BMP9. Neither BMP9 nor BMP10 has been implicated
previously in skeletal development. BMP9 is produced in the
liver and is present in the circulation at high enough levels to
activate BMP signaling (36, 58, 62). BMP10 is predominantly
expressed in the heart and is in the circulation, but at lower levels
than BMP9 (40, 63). Although neither BMP9 nor BMP10 is
produced in cartilage (SI Appendix, Fig. S2) (38, 39), BMP9
protein is present in growth plate chondrocytes. We speculate
that the BMP9 in the growth plate is derived from the circula-
tion, as high levels were detected in blood vessels and tissues
close to the growth plate. Although the mechanisms are un-
known, even large molecules can diffuse through dense cartilage
extracellular matrix (64).
We consistently observed elevated basal BMP signaling in
Tgfbr1Δ/Δ cells. The elevated basal signaling is due to activity of
ACVRL1 because it was blocked by a mutation that inactivated
ACVRL1 kinase activity. However, we were unable to find evi-
dence that the basal activity is ligand dependent. Experiments
were performed under serum-free conditions; NOGGIN, anti-
BMP9 antibody, ACVRL1-Fc, or ACTRIIB-Fc did not block the
increased basal signaling. NOGGIN binds to BMPs 2 and 4 to
7 and GDFs 5 to 7 at the concentrations used here, but does not
block BMP9 and BMP10 (33, 65, 66). ACVRL1-Fc blocks
BMP9 and BMP10. ACTRIIB-Fc blocks multiple ligands in-
cluding activins, GDF8, and GDF11 (67, 68). We cannot rule out
an effect due to increased levels of an untested ligand, nor can
we rule out an effect mediated by altered levels of expression of
BMP receptors. qRT-PCR experiments revealed that levels of
Bmpr1a are reduced in Tgfbr1Col2 chondrocytes (SI Appendix,
Fig. S2). Although this would typically be expected to reduce
BMP signaling, Antebi et al. (69) showed that altering relative
levels of BMPs receptors can greatly alter responsiveness to
specific ligand pairs, enabling some pairs to switch from an an-
tagonistic to an additive mode. An analysis of responsiveness of
Tgfbr1Col2 chondrocytes to multiple pairs to BMP ligands will be
needed to assess how loss of TGFβRI impacts signaling by mul-
tiple ligands through each BMP receptor complex. It is conceiv-
able that the elevated basal BMP activity in Tgfbr1Δ/Δ cells involves
a ligand-independent effect of ACVRL1. Forced expression of
ACVRL1 increases basal BMP activity (30, 70, 71). Fluid flow can
trigger ligand-independent activation of BMP signaling in vascular
tissues (72), and/or can greatly increase sensitivity of ACVRL1 to
BMP9 (73). As cartilage experiences mechanical strain in vivo, it
will be of interest to test how mechanical forces impact BMP
signaling through ACVRL1 in cartilage.
In summary, contradictory to the paradigm, the major role of
TGFβRI in growth plate chondrocytes is not to transduce TGFβ
signaling, but rather to block ACVRL1-mediated BMP signaling.
It is possible that TGFβRI exerts its effects by blocking ACVRL1-
mediated BMP signaling in tissues other than growth plate cartilage.
Materials and Methods
Mouse Lines and Breeding.All procedures involving animals were approved by
the Institutional Animal Care and Use Committee of University of California,
Los Angeles. Mice were housed in an Association for Assessment and Ac-
creditation of Laboratory Animal Care-accredited facility in accordance with
the Guide for the Care and Use of Laboratory Animals (74). This study was
compliant with all relevant ethical regulations regarding animal research.
E12.5–E18.5 embryos from C57BL6 backgrounds were used. Both sexes were
used as sex was not determined in embryos. To genotype Tgfbr1-flox mice,
3 primers were used: 5′-ATGAGTTATTAGAAGTTGTTT-3′, 5′-ACCCTCTCA-
CTCTTCCTGAGT-3′, and 5′-GGAACTGGGAAAGGAGATAAC-3′, with 55 °C
annealing temperature, yielding 350-bp wild-type (WT) and 150-bp flox-
inserted mutant bands (75). To genotype Acvrl1-flox mice, 2 primers were
used: 5′-CCTGGACAGCGACTGTACTAC-3′ and 5′-GCCCCATTGCTCTCCTCAA-
AC-3′, with 68 °C annealing temperature, yielding 450-bp WT and 350-bp
flox-inserted mutant bands (50). To genotype Col2a1-Cre mice, 2 primers
were used: 5′-TGCTCTGTCCGTTTGCCG-3′ and 5′-ACTGTGTCCAGACCAGGC-
3′, with 58 °C annealing temperature, yielding a 800-bp band (44).
IHC and TUNEL Assay. Limb tissues were dissected and fixed in 4% para-
formaldehyde in PBS. They were then decalcified with Immunocal (Decal
Chemical Corporation) for 3 d at 4 °C, embedded in paraffin, and cut at a
thickness of 7 μm. Paraffin sections were deparaffinized and rehydrated by
passage through xylene and 100%, 95%, and 70% ethanol. Samples were
treated with 1 mg/mL hyaluronidase for 30 min at 37 °C. Sections were
blocked with 5% goat or donkey serum, in TBS for 1 h at room temperature
and incubated with 1:200 diluted primary antibody at 4 °C overnight. Slides
were washed 3 times in TBST for 10 min each and incubated at room tem-
perature for an hour in secondary antibody (1:500) conjugated with fluores-
cent dyes (Cell Signaling; goat anti-rabbit red, R37117; goat anti-rabbit green,
R37116; goat anti-mouse red, A11032) in 1% goat or donkey serum TBST.
Slides were washed 3 times in PBST for 10 min each and stained in DAPI
(Sigma; D9453) at 0.1 μg/mL for 10 min. Lastly, the slide was mounted in 10 μL
of Fluoro-Gel (Electron Microscopy Sciences; 1798510). Primary antibodies
included the following: α-TGFβRI (Abcam; 31013), α-ACVRL1 (Santa Cruz;
19546), α-pSMAD1/5/8 (Cell Signaling; 9511S), α-pSMAD2/3 (Cell Signaling;
3108S), α-PCNA (Abcam; 2586S), α-TAK1(Cell Signaling; 4508S), and α-BMP9
(R&D; AF3209). Apoptotic cells were detected by in situ TUNEL assay using the
In Situ Cell Death Detection Kit (Sigma; 11684795910) following the manu-
facturer’s instructions. All experiments were repeated on sections from at
least 3 embryos of each genotype. All comparisons were between littermates.
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Skeletal Preparation and Histology.Whole-mount skeletal preparations (n = 5)
were performed as described (33). For histological analyses, paraffin sections
were produced from E13.5, E16.5, E18.5, and postnatal day 0 (P0) mice.
Safranin-O staining was performed as described (76). Heights of RZ, CZ, and
HZ were measured directly from images (n = 4) taken from each of 4 mice per
genotype, and significance was evaluated using Student’s 2-tailed t test.
RNA Isolation and qPCR. Limb joint cartilages isolated from E17.5 mice were
frozen in liquid nitrogen and smashed to powder. Cartilage powder was then
fixed in TRIzol. Total RNAwas isolated by the phenol-chloroformmethod and
converted to cDNA. The cDNA was amplified and quantified using SYBR
Green reagent (Sigma) in a Stratagene Mx3005P qPCR System (Thermo Sci-
entific). Primer sequences are shown in SI Appendix, Table S1.
Co-IP. Immunoprecipitations (IPs) were performed using Pierce Crosslink
Magnetic IP/Co-IP kit (Thermo Scientific; 88805). To obtain the lysate solution,
confluent ATDC5 cells in 150-mm dishes were fixed in 1% formaldehyde at
room temperature for 10 min followed by quenching with 125 mM glycine at
room temperature for 5 min. Fixed cells were washed with cold PBS twice.
Cells were collected by scraper and centrifuged at 750 × g for 4 min and then
resuspended in PBS supplemented with protease inhibitors mixture (Thermo
Scientific). Cross-linking was performed on the suspended cells using dis-
uccinimidyl suberate (Thermo Scientific) with a final concentration of
2.5 mM. The reaction was allowed to proceed for 30 min at room temper-
ature before quenching with Tris with a final concentration of 20 mM. After
centrifugation at 750 × g for 4 min, cell pellet was resuspended in 500 μL of
IP Lysis Buffer from the kit supplemented with protease inhibitors. Lysate
was sonicated in an ice-water bath for cell disruption. After IP was per-
formed with antibodies listed in SI Appendix, Table S1. The pull-down
products were analyzed by Western blot.
Western Blot Analysis. Protein samples were heated in Laemmli buffer at 95 °C
for 5 min. Thirty to 50 μg of protein was subjected to sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis and transferred onto nitrocellulose
membranes. After blocking, the membranes were probed with appropriate
primary antibodies and then incubated with specific horseradish peroxidase-
conjugated secondary antibodies (Bio-Rad). Immunodetection was performed
using enhanced chemiluminescence consistent with the manufacturer’s pro-
tocol (Thermo Fisher Scientific). The band intensities were quantified and
normalized to the corresponding controls. The antibodies used are listed in SI
Appendix, Table S1.
DNA Transfection and Reporter Assay. ATDC5 cells were plated in 48-well
plates at a density of 2.0 × 104 cells per well in Dulbecco’s modified Ea-
gle’s medium (DMEM) (Corning) containing 10% fetal bovine serum (FBS)
and 1% streptomycin/penicillin. After 1 h, the cells were transfected in
quadruplicates with PolyJet reagent. In total, 0.05 μg of Renilla plasmids
(Addgene) and 0.1 μg of 12× SBE-Luc (77) plasmids with 0.75 μL of PolyJet
reagent were added per well. The cells were grown overnight at 37 °C with
CO2. Twenty-four hours posttransfection, medium was replaced with serum-
free DMEM containing 200 μg/mL ascorbic acid and 1% streptomycin/penicil-
lin. After 3 h of starvation, cells were treated with various ligands, Fc-proteins,
and antibodies: TGFβ1, 5 ng/mL (R&D 240-B); BMP2, 200 ng/mL (R&D; 355-BM);
BMP9, 100 ng/mL (Biolegend; 553102); NOGGIN, 400 ng/mL (R&D; 1967-NG);
anti-BMP9, 400 ng/mL (R&D; MAB3209); ACVRL1-Fc, 400 ng/mL (R&D; 370-AL);
ACTRIIB-Fc, 400 ng/mL (R&D; 3725-RB); anti-ACVRL1, 400 ng/mL (Santa
Cruz; 19546); and anti-ACTRIIB, 400 ng/mL (Santa Cruz; 25453). Twenty-four
hours posttreatment, growth media was removed. Then, the cells were washed
with PBS and lysed in 0.1 mL of Passive Lysis Buffer (PLB). Dual-luciferase re-
porter assay was performed using the Promega kit (E1910) in a FLUOstar
Omega system (BMG Labtech) following the manufacturer’s instructions. Data
are presented as ratios of Luc/Renilla activity.
CRISPR-Cas9 Gene Editing. Oligos that target Tgfbr1 were synthesized and
linked to lentiCRISPRv2 (1-vector system) plasmid as described (78). Oligo
sequences for Tgfbr1 were as follows: 5′-CACCGCCTCTTCATTTGGCACACGG-
3′ and 5′-AAACCCGTGTGCCAAATGAAGAGGC-3′. ATDC5 cells were seeded in
6-well plates at a density of 1 × 106 cells per well in DMEM containing 10%
FBS and 1% penicillin/streptomycin. After 24 h, the cells were transfected
with 1 μg of lentiCRISPRv2 plasmid and 3 μL of Lipofectamine (SignaGen) per
well. After 2 d of transfection, Tgfbr1 mutant cells (Tgfbr1Δ/Δ) were selected
with puromycin at 4 μg/mL. Mutation of Tgfbr1 was confirmed by PCR. The
PCR used were 5′-GCTTCGTCTGCATTGCACTT-3′ and 5′-AGGTGGTGCCCTCT-
GAAATG-3′. WT allele has a 126-bp PCR product, and Tgfbr1 deletion-
mutant allele has no PCR product. Loss of TGFβRI protein was confirmed
by Western blot using anti-TGFβRI antibody (Abcam; ab31013). For gener-
ating the Acvrl1 kinase mutation, ATDC5 cells were transfected with RNA
oligos (CRISPR RNA [crRNA] and transactivating crRNA [tracrRNA]) and
single-stranded DNA oligonucleotides (ssODNs). crRNA was designed as 5′-
UGGUGCAGAGGACGGUAGCUGUUUUAGAGCUAUGCU-3′ and ordered from
Integrated DNA Technologies (IDT); tracrRNA was ordered from IDT; ssODN
was designed as 5′-GCAGCGGCTCGGGGCTCCCCTTCTTGGTGCAGAGGGTGG-
TAGCTCGGCAGGTTGCGCTGGTAGAGTGTGTGG-3′. RNA oligos (crRNA and
tracrRNA) were mixed in equimolar concentrations to a final duplex con-
centration of 50 μM. The mix was heated at 95 °C for 5 min and allowed to
cool to room temperature (15 to 25 °C). For each sample, crRNA:tracrRNA
(50 μM working solution) was diluted in their respective buffers to a final
volume of 6 μL each. Tgfbr1Δ/Δ cells were transfected with 6 μL of crRNA:tracrRNA
(50 μM), 3 μL of ssODN (100 μM), 1 μL of pLentiCas9-Blast plasmid (0.1 μg/μL;
Genscript), and 4 μL of Lipofectamine (SignaGen) per well (24-well plate).
After 2 d of transfection, Acvrl1 mutant cells were screened by single-cell colony
culture and PCR. PCR primers targeting theAcvrl1mutant allele were designed as
5′-CTAGGACTTCCTGGACAGCG-3′ and 5′-CAGCCCGTTGAGTGCTTACC-3′. Mutation
in Acvrl1 was confirmed by sequencing.
PLA. PLA was performed directly after IHC following manufacturer’s in-
structions (Sigma-Aldrich; Duolink PLA Technology). After blocking, sections
were incubated with goat anti-ACVRL1 (5 μg/mL; Santa Cruz; 15946), rabbit
anti-TGFβR1 (5 μg/mL; Abcam; 31013), and rabbit anti-ACTRIIB (5 μg/mL;
Santa Cruz; 25453) antibodies overnight at 4 °C, followed by incubation with
secondary antibodies conjugated with PLA probe at 37 °C for 1 h as rec-
ommended by manufacturers. Then, ligation and amplification were per-
formed (Duolink detection kit; orange, 555 nm). Finally, mounting medium
with DAPI was used.
Statistical Analysis. Statistical comparisons were made between 2 groups
using Student’s t test; P values of <0.05 were considered significant. For
multiple comparisons, we performed 2-way ANOVA (2 factor with replica-
tion) analysis, followed by post hoc tests that uses t test to compare 2 groups
and controls the familywise error rate by Bonferroni correction of P values
(0.05/n, n = number of groups).
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